Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07570966 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

217

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced HR+/HER2- Breast Cancer
Advanced CCNE1-amplified Solid Tumors
Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG: ERW316
DRUG: Fulvestrant
DRUG: Letrozole

Sponsor

Novartis Pharmaceuticals